Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence

Dimethyl fumarate (DMF) is an oral disease-modifying therapy approved for management of relapsing-remitting multiple sclerosis patients. Results from phase 3 clinical trials (DEFINE, CONFIRM) and follow-up study (ENDORSE) have provided good evidence for its efficacy and safety profile. Patient-repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Narapureddy, Bhavya, Dubey, Divyanshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778444/
https://www.ncbi.nlm.nih.gov/pubmed/31631980
http://dx.doi.org/10.2147/PPA.S187529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778444/
https://www.ncbi.nlm.nih.gov/pubmed/31631980
http://dx.doi.org/10.2147/PPA.S187529

Ejemplares similares